Brief: Cantex Pharmaceuticals Initiation Of Phase 2/3 Study To Determine Safety, Efficacy Of Azeliragon In Treatment Of Patients Hospitalized For Covid-19
20/04/2023 13:23
April 20 (Reuters) - vTv Therapeutics Inc VTVT.O :
* CANTEX PHARMACEUTICALS: INITIATION OF PHASE 2/3 STUDY TO
DETERMINE SAFETY, EFFICACY OF AZELIRAGON IN TREATMENT OF
PATIENTS HOSPITALIZED FOR COVID-19
Source text for Eikon: ID:
Further company coverage: VTVT.O
Recent news on vTv Therapeutics
See all newsBrief: Vtv Therapeutics Announces FDA Orphan Drug Designation For Hppd In Sickle Cell Disease
vTv Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
vTv Therapeutics Inc expected to post a loss of $1.04 a share - Earnings Preview
vTv Therapeutics Q2 net loss widens on higher trial costs
Brief: VTv Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)